WenLi Tan1, Ji Xiong2, WeiYuan Huang3, JinSong Wu4, SongHua Zhan1, DaoYing Geng5. 1. Department of Radiology, Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. 2. Department of Neuropathology, Huashan Hospital, Fudan University, Shanghai, P.R. China. 3. Department of Radiology, Hainan General Hospital, Hainan Province, P.R. China. 4. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P.R. China. 5. Department of Radiology, Huashan Hospital, Fudan University, Shanghai, P.R. China.
Abstract
PURPOSE: To investigate the value of dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) in the noninvasive evaluation of isocitrate dehydrogenase (IDH) 1 gene status in astrocytoma. MATERIALS AND METHODS: The preoperative DSC MRI data of 91 lesions with pathologically confirmed astrocytoma were retrospectively analyzed. MR examination was performed on a 3T MRI scanner. The normalized maximum ratios of relative cerebral blood volume (rCBV ratio) of tumor parenchyma were measured. The enrolled astrocytoma patients were divided into six groups according to the World Health Organization (WHO) classification method and IDH1 gene status. The differences in the rCBV ratio of tumor parenchyma between the IDH1 gene mutant and wildtype groups of WHO grade II, III, and IV were compared and plotted receiver operating characteristic (ROC) curves were drawn. RESULTS: The IDH1 gene mutant and wildtype groups of WHO grade II, III, and IV astrocytoma showed differences in the rCBV ratio (P = 0.005, 0.045, and 0.005, respectively). In WHO grade II, III, and IV astrocytoma, the area under the ROC curve was respectively 0.83, 0.86, and 0.94. The cutoff value of the rCBV ratio was respectively 2.20, 3.14, and 5.63. CONCLUSION: The rCBV ratio value provided by DSC MRI provides a new potential imaging method for the noninvasive evaluation of the IDH1 status in astrocytoma. LEVEL OF EVIDENCE: 3 J. Magn. Reson. Imaging 2017;45:492-499.
PURPOSE: To investigate the value of dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) in the noninvasive evaluation of isocitrate dehydrogenase (IDH) 1 gene status in astrocytoma. MATERIALS AND METHODS: The preoperative DSC MRI data of 91 lesions with pathologically confirmed astrocytoma were retrospectively analyzed. MR examination was performed on a 3T MRI scanner. The normalized maximum ratios of relative cerebral blood volume (rCBV ratio) of tumor parenchyma were measured. The enrolled astrocytomapatients were divided into six groups according to the World Health Organization (WHO) classification method and IDH1 gene status. The differences in the rCBV ratio of tumor parenchyma between the IDH1 gene mutant and wildtype groups of WHO grade II, III, and IV were compared and plotted receiver operating characteristic (ROC) curves were drawn. RESULTS: The IDH1 gene mutant and wildtype groups of WHO grade II, III, and IV astrocytoma showed differences in the rCBV ratio (P = 0.005, 0.045, and 0.005, respectively). In WHO grade II, III, and IV astrocytoma, the area under the ROC curve was respectively 0.83, 0.86, and 0.94. The cutoff value of the rCBV ratio was respectively 2.20, 3.14, and 5.63. CONCLUSION: The rCBV ratio value provided by DSC MRI provides a new potential imaging method for the noninvasive evaluation of the IDH1 status in astrocytoma. LEVEL OF EVIDENCE: 3 J. Magn. Reson. Imaging 2017;45:492-499.
Authors: Shanshan Jiang; Tianyu Zou; Charles G Eberhart; Maria A V Villalobos; Hye-Young Heo; Yi Zhang; Yu Wang; Xianlong Wang; Hao Yu; Yongxing Du; Peter C M van Zijl; Zhibo Wen; Jinyuan Zhou Journal: Magn Reson Med Date: 2017-07-16 Impact factor: 4.668
Authors: E Aliotta; H Nourzadeh; P P Batchala; D Schiff; M B Lopes; J T Druzgal; S Mukherjee; S H Patel Journal: AJNR Am J Neuroradiol Date: 2019-08-14 Impact factor: 3.825
Authors: Kevin Leu; Garrett A Ott; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; William H Yong; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson Journal: J Neurooncol Date: 2017-05-25 Impact factor: 4.130
Authors: Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain Journal: J Neurooncol Date: 2021-03-04 Impact factor: 4.130